Department of Neurosurgery, University of Utah, Salt Lake City, UT, USA.
J Neurosurg. 2013 Aug;119(2):338-46. doi: 10.3171/2013.4.JNS121541. Epub 2013 May 24.
Normal intracranial pressure (ICP) and cerebral perfusion pressure (CPP) have been identified as favorable prognostic factors in the outcome of patients with traumatic brain injuries (TBIs). Osmotic diuretics and hypertonic saline (HTS) are commonly used to treat elevated ICP in patients with TBI; however, sustained effects of repeated high-concentration HTS boluses for severely refractory ICP elevation have not been studied. The authors' goal in this study was to determine whether repeated 14.6% HTS boluses were efficacious in treating severely refractory intracranial hypertension in patients with TBI.
In a prospective cohort study in a neurocritical care unit, adult TBI patients with sustained ICP > 30 mm Hg for more than 30 minutes after exhaustive medical and/or surgical therapy received repeated 15-minute boluses of 14.6% HTS over 12 hours through central venous access.
Response to treatment was evaluated in 11 patients. Within 5 minutes of bolus administration, mean ICP decreased from 40 to 33 mm Hg (30% reduction, p < 0.05). Intracranial pressure-lowering effects were sustained for 12 hours (41% reduction, p < 0.05) with multiple boluses (mean number of boluses 7 ± 5.5). The mean CPP increased 22% and 32% from baseline at 15 and 30 minutes, respectively (p < 0.05). The mean serum sodium level (SNa) at baseline was 155 ± 7.1 mEq/L, and after multiple boluses of 14.6% HTS, S(Na) at 12 hours was 154 ± 7.1 mEq/L. The mean heart rate, systolic blood pressure, blood urea nitrogen, and creatinine demonstrated no significant change throughout the study.
The subset of TBI patients with intracranial hypertension that is completely refractory to all other medical therapies can be treated effectively and safely with repeated boluses of 14.6% HTS rather than a one-time dose.
正常颅内压(ICP)和脑灌注压(CPP)已被确定为颅脑损伤(TBI)患者预后的有利因素。渗透性利尿剂和高渗盐水(HTS)常用于治疗 TBI 患者的颅内压升高;然而,尚未研究重复给予高浓度 HTS 推注治疗严重难治性颅内压升高的持续效果。作者在这项研究中的目的是确定重复给予 14.6% HTS 推注是否对治疗 TBI 患者严重难治性颅内高压有效。
在神经重症监护病房的前瞻性队列研究中,经过充分的药物和/或手术治疗后 ICP 仍持续>30 分钟>30mmHg 的成年 TBI 患者,通过中心静脉通路在 12 小时内接受重复 15 分钟的 14.6% HTS 推注。
在 11 例患者中评估了治疗反应。推注后 5 分钟内,平均 ICP 从 40mmHg 降至 33mmHg(降低 30%,p<0.05)。颅内压降低作用持续 12 小时(降低 41%,p<0.05),重复推注(平均推注次数 7±5.5 次)。CPP 在 15 分钟和 30 分钟时分别比基线增加 22%和 32%(p<0.05)。基线时血清钠水平(SNa)为 155±7.1mEq/L,重复给予 14.6% HTS 后 12 小时 SNa 为 154±7.1mEq/L。整个研究过程中,平均心率、收缩压、血尿素氮和肌酐均无明显变化。
对于所有其他药物治疗均完全无效的颅内高压 TBI 患者亚组,可以安全有效地用重复给予 14.6% HTS 推注而不是单次剂量来治疗。